메디채널

주메뉴 바로가기
본문 바로가기

기상청 제공

닫기

라이프

Boehringer Ingelheim and Simcere partner to advance a dual-target antibody treatment to address unmet needs in inflammatory bowel disease

[ 메디채널 김갑성 기자 ] Novel TL1A/IL23p19 bispecific antibody targets drivers of disease pathogenesis to overcome the efficacy ceiling in inflammatory bowel disease. License and collaboration agreement strengthen Boehringer's inflammatory disease pipeline with a potential, first-in-class, pre-clinical asset. Boehringer receives global rights to the asset, excluding greater China; Simcere is eligible to receive payments of up to EUR 1,058 million SHANGHAI, Jan. 27, 2026 -- Simcere Pharmaceutical Group Ltd. ("Simcere") (HKEX: 2096) and Boehringer Ingelheim, today announced a
- 김갑성 기자
- 2026-01-27 18:40
Libevitug Approved in China as First-in-Class Treatment for Hepatitis D

BEIJING, Jan. 27, 2026 -- Huahui Health announced that China National Medical Products Administration (NMPA) has granted conditional approval to its Libevitug injection for the treatment of chronic hepatitis D virus infection in adults with or without compensated cirrhosis. Libevitug is a human monoclonal antibody targeting the PreS1 domain of the large envelope protein of hepatitis B virus (HBV) and hepatitis D virus (HDV), thereby blocking viral entry into hepatocytes. As a groundbreaking achievement in viral hepatitis therapeutics, Libevitug is a first-in-class antibody therapeutic for vir
- 김갑성 기자
- 2026-01-27 16:18
Libevitug Approved in China as First-in-Class Hepatitis D Treatment

BEIJING, Jan. 27, 2026 -- Huahui Health announced that China's National Medical Products Administration (NMPA) has granted conditional approval to its Libevitug injection for chronic hepatitis D virus (HDV) infection in adults with or without compensated cirrhosis. Libevitug is a human monoclonal antibody targeting the PreS1 domain of hepatitis B virus (HBV) and HDV envelope proteins, blocking viral entry into hepatocytes. As a groundbreaking advance in viral hepatitis care, it is China's first approved HDV therapy and a first-in-class antibody for viral hepatitis, addressing a critical clini
- 김갑성 기자
- 2026-01-27 16:15
Servier delivers solid performance in 2024/25 and confirms its forecasts for 2030

Servier reported Group revenues of €6.9 billion for 2024/25, up 16.2% from 2023/24. Growth over the financial year was driven by increased sales in oncology, particularly in the United States. Several partnership agreements in oncology and neurology strengthen the Group's R&D portfolio in rare diseases. Achieving 2025 targets reflects successful transformation that began in 2015 and underpins the Group's ambitions for 2030. SURESNES, France, Jan. 27, 2026 -- Servier, an independent international pharmaceutical group governed by a foundation, published its financi
- 김갑성 기자
- 2026-01-27 16:00
3Shape appoints Rasmus Hannemann as Senior Vice President, Portfolio & Product Strategy

COPENHAGEN, Denmark, Jan. 27, 2026 -- 3Shape today announced the appointment of Rasmus Hannemann as Senior Vice President, Portfolio & Product Strategy, effective 9 March. Rasmus will step into the Senior Leadership Team and will report directly to CEO Jacob Paulsen. Rasmus joins 3Shape from Coloplast, where he spent more than 20 years in senior leadership roles spanning strategy, product management, marketing, and global business leadership. Most recently, he served as Vice President, Group Development & Strategy, with responsibility for corporate strategy, M&A, and post-m
- 김갑성 기자
- 2026-01-27 15:45
Getinge Q4 and Full-Year Report 2025: Organic growth and solid cash flow to end the year

GOTHENBURG, Sweden, Jan. 27, 2026 -- "We succeeded in growing organically, delivering a record-breaking fourth quarter and organic growth at the upper end of our forecast, 4.9% for the full year," says Mattias Perjos, President & CEO at Getinge. Higher demand for consumables for ECLS-therapy in the quarter and in Acute Care Therapies contributed to Getinge's performance. Sales were also strong in Transplant Care and ventilators. Surgical Workflows continued to strengthen its market-leading position in operating tables and enters 2026 with robust order bookings. In general
- 김갑성 기자
- 2026-01-27 15:23
Davos Spotlight | EVYD, Ministry of Health Brunei Darussalam and Novartis Foundation Launch National AI-Powered Cardiovascular Disease Prevention Initiative

DAVOS, Switzerland, Jan. 27, 2026 -- At the 2026 World Economic Forum Annual Meeting in Davos, Dr. Giovanni Caforio, Chairman of the Board of Directors of Novartis, announced a major new partnership: the Novartis Foundation, the Ministry of Health of Brunei Darussalam, and EVYD Technology will jointly implement an AI- and data-enabled national cardiovascular disease prevention initiative under the global program: CARDIO4Cities. Built on Brunei's national health platform, the program aims to harness population-scale data and artificial intelligence to enable early identification of high
- 김갑성 기자
- 2026-01-27 14:37
Nuance Pharma Announces Acceptance for Review of the New Drug Application for Ohtuvayre® (ensifentrine) by the National Medical Products Administration of China for the maintenance treatment of chronic obstructive pulmonary disease

SHANGHAI, Jan. 27, 2026 -- Nuance Pharma ("Nuance") today announced that the National Medical Products Administration (NMPA) of China has officially accepted for review the New Drug Application (NDA) for Ohtuvayre® (ensifentrine) for the maintenance treatment of chronic obstructive pulmonary disease. Ohtuvayre® is a first-in-class selective dual inhibitor of phosphodiesterase 3 and 4 ("PDE3 and PDE4") that combines bronchodilator and non-steroidal anti-inflammatory effects in one molecule, delivered directly to the lungs through a standard jet nebulizer.&nbs
- 김갑성 기자
- 2026-01-27 10:13
Unlock the Future of Health and Food Innovation: Hi & Fi Asia-China 2026 Pre-Registration Now Open

SHANGHAI, Jan. 27, 2026 -- Leveraging the solid foundation laid by its highly renowned 2025 edition, Hi & Fi Asia-China, Asia's premier platform for health ingredients and food innovation, is delighted to announce the official launch of pre-registration for its 2026 edition. Scheduled to be held from 15-17 June 2026 at the National Exhibition and Convention Center (NECC) Shanghai, the event will serve as a vital hub for global industry leaders, innovators, and decision-makers to converge, collaborate, and explore new possibilities in the dynamic food and health innovation landscape.
- 김갑성 기자
- 2026-01-27 10:00
Alphamab Oncology Announces the Results of a Phase III Clinical Study of Anbenitamab (KN026) were Published in Annals of Oncology

SUZHOU, China, Jan. 27, 2026 -- Alphamab Oncology (Stock Code: 9966.HK) announced that the results from a phase III clinical study for the treatment of HER2-positive gastric or gastroesophageal junction cancer (GC/GEJ) of anbenitamab injection (KN026), independently developed by the Company and co-developed with JMT-Bio Technology Co., Ltd., a wholly-owned subsidiary of CSPC Pharmaceutical Group Co., Ltd. (stock code: 1093.HK), were recently published in the top-tier oncology journal Annals of Oncology (IF:65.4). The publication is titled: "Anbenitamab in previously treated HER2-positive
- 김갑성 기자
- 2026-01-27 09:58

이전

21 22 23 24 25 26 27 28 29 30

많이 본 기사

최근기사

2026-03-03_TUE

Innovaccer Receives Frost & Sullivan's 2026 United States New Product Innovation Recognition for Excellence in AI-Driven Patient Access Solutions 00:57

2026-03-02_MON

발행인 : 최희정 | 편집인 : 김갑성 |
등록번호: 서울특별시 아53302 | 등록일 2020-09-25 | 전화번호 02-565-7119 |
주소 : 서울특별시 강남구 영동대로 602, 6층 E115 (삼성동)
Copyright @메디채널 Corp. All rights reserved.

UPDATE: 2026년 03월 03일 02시 40분